Aurobindo Pharma is working on developing several viral vaccines including one for COVID-19 even as the candidate was approved for funding by the Department of BioTechnology. During the year (FY20), the company has further strengthened its presence in the vaccines segment through the acquisition of R&D assets from Profectus Biosciences through Auro Vaccines. Using those R&D assets, the team is working on developing several viral vaccines, including a vaccine for COVID-19.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
